Skip to main content
TipRanks
Go Ultimate75% OFF

Hanall Biopharma Co., Ltd. (009420) Stock Statistics & Valuation Metrics

Total Valuation

Hanall Biopharma Co., Ltd. has a market cap or net worth of KRW 2.72T. The enterprise value is KRW 2.26T.

Market Cap
KRW 2.72T
Enterprise Value
KRW 2.26T

Share Statistics

Hanall Biopharma Co., Ltd. has 52,240,640 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
52,240,640
Owned by Insiders
―
Owned by Institutions
5.13%

Financial Efficiency

Hanall Biopharma Co., Ltd.’s return on equity (ROE) is -0.03 and return on invested capital (ROIC) is -0.74%.

Return on Equity (ROE)
-0.03
Return on Assets (ROA)
-0.02
Return on Invested Capital (ROIC)
-0.74%
Return on Capital Employed (ROCE)
-0.01
Revenue Per Employee
492.65M
Profits Per Employee
-17.65M
Employee Count
315
Asset Turnover
0.69
Inventory Turnover
2.00

Valuation Ratios

The current PE Ratio of Hanall Biopharma Co., Ltd. is -122.17. Hanall Biopharma Co., Ltd.’s PEG ratio is -0.17.

PE Ratio
-122.17
PS Ratio
16.44
PB Ratio
17.74
Price to FCF
-340.32
Price to Operating Cash Flow
-395.32
PEG Ratio
-0.17

Income Statement

In the last 12 months, Hanall Biopharma Co., Ltd. had revenue of 155.18B and earned -5.56B in profits. Earnings per share was -111.55.

Revenue
155.18B
Gross Profit
79.10B
Operating Income
-1.61B
Pretax Income
-6.18B
Net Income
-5.56B
EBITDA
1.94B
Earnings Per Share (EPS)
-111.55

Cash Flow

In the last 12 months, operating cash flow was -6.91B and capital expenditures -904.45M, giving a free cash flow of -7.82B billion.

Operating Cash Flow
-6.91B
Free Cash Flow
-7.82B
Free Cash Flow per Share
-149.61

Dividends & Yields

Hanall Biopharma Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-0.29%
Earnings Yield
-0.81%

Stock Price Statistics

Beta
0.48
52-Week Price Change
15.84%
50-Day Moving Average
44377.00
200-Day Moving Average
51430.75
Relative Strength Index (RSI)
66.58
Average Volume (3m)
267.36K

Important Dates

Hanall Biopharma Co., Ltd. upcoming earnings date is Jan 20, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 13, 2026
Next Earnings Date
Jan 20, 2027
Ex-Dividend Date
―

Financial Position

Hanall Biopharma Co., Ltd. as a current ratio of 1.91, with Debt / Equity ratio of 19.74%

Current Ratio
1.91
Quick Ratio
1.05
Debt to Market Cap
0.01
Net Debt to EBITDA
3.70
Interest Coverage Ratio
-11.31

Taxes

In the past 12 months, Hanall Biopharma Co., Ltd. has paid -621.61M in taxes.

Income Tax
-621.61M
Effective Tax Rate
0.10

Enterprise Valuation

Hanall Biopharma Co., Ltd. EV to EBITDA ratio is -208.72, with an EV/FCF ratio of -342.44.

EV to Sales
16.55
EV to EBITDA
-208.72
EV to Free Cash Flow
-342.44
EV to Operating Cash Flow
-387.26

Balance Sheet

Hanall Biopharma Co., Ltd. has KRW 23.32B in cash and marketable securities with KRW 39.90B in debt, giving a net cash position of -KRW 16.58B billion.

Cash & Marketable Securities
KRW 23.32B
Total Debt
KRW 39.90B
Net Cash
-KRW 16.58B
Net Cash Per Share
-KRW 317.36
Tangible Book Value Per Share
KRW 1,867.92

Margins

Gross margin is 51.29%, with operating margin of 3.00%, and net profit margin of -13.69%.

Gross Margin
51.29%
Operating Margin
3.00%
Pretax Margin
-15.50%
Net Profit Margin
-13.69%
EBITDA Margin
-7.93%
EBIT Margin
-9.88%

Analyst Forecast

The average price target for Hanall Biopharma Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
5.00%
EPS Growth Forecast
-1058.77%

Scores

Smart Score
―
AI Score
52